Assenagon Asset Management S.A.
Position in FULC — Fulcrum Therapeutics, Inc.
CIK 1546007
SENNINGERBERG, N4
Position in FULC
as of Mar 31, 2026
· filed Apr 20, 2026
Position Value
$9,157,005
+$7,941,438 QoQ
Shares Held
1,193,873
+250.6% QoQ
Ownership
1.79%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#20
of 168 holders
Holding Since
Jun 2024
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in FULC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Assenagon Asset Management S.A. holds $1,400,134,578 across 60 Biotechnology names. FULC ranks #19 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
537,248 | $239,902,721 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
7,076,488 | $196,018,717 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
207,788 | $160,545,320 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
865,958 | $146,364,221 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
1,920,658 | $108,497,970 | |
| 6 | TARS |
Tarsus Pharmaceuticals, Inc.
|
1,280,194 | $89,805,609 | |
| 7 | PCVX |
Vaxcyte, Inc.
|
1,164,813 | $67,687,283 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
320,000 | $60,496,000 |
All Filings in FULC
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,157,005 | 1,193,873 | Shares | Sole | 2026-04-20 | |
| 2024-09-30 | $1,215,567 | 340,495 | Shares | Sole | 2024-10-23 | |
| 2024-06-30 | $3,084,227 | 497,456 | Shares | Sole | 2024-07-18 | |
| No filing history on record for this holder in this stock. | ||||||